|
Health Care Reform Law: Five Strategy Decisions
to Make Now
A phase-by-phase approach to addressing the critical aspects of the bill
impacting Biopharma and Medical Device Companies.
Click Here to view the archived webinar
(taped Friday, April 23rd, 2010).
A round table discussion moderated by
Ron Kraus, Vice President, Global Customer Strategy, PAREXEL Consulting.
Panelists:
Saurabh Aggarwal, PhD, Principal Consultant,
Reimbursement & Market Access, PAREXEL Consulting
Paul Bridges, PhD, Vice President, Global Product Development, PAREXEL Consulting
Chuck Stevens, VP & GM, Reimbursement & Market Access, PAREXEL Consulting
Ramita Tandon, Senior Director, Late Phase, PAREXEL Clinical Research
Followed by Q&A with the audience.
If you are interested in an Executive Briefing, in-house training or to speak to someone about the impact of Health Care Refrom Law in the US, please e-mail: mailto:chad.simon@parexel.com
PAREXEL Consulting provides integrated product development consulting services, helping biopharmaceutical and medical device companies shorten time to market and maintain product viability for the long-term. Through our unique fusion of scientific, regulatory, and business expertise, we also help clients manage risk, and maximize product and portfolio value at every milestone and phase of development worldwide.
Pharmaceutical | Biotech | Medical Device | Combination
Product Development and Commercialization Experts
|
